Table of Contents
ISRN Pharmacology
Volume 2013 (2013), Article ID 794582, 8 pages
http://dx.doi.org/10.1155/2013/794582
Research Article

Synthesis of Alginate-Curcumin Nanocomposite and Its Protective Role in Transgenic Drosophila Model of Parkinson’s Disease

1Drosophila Transgenic Laboratory, Section of Genetics, Department of Zoology, Faculty of Life Sciences, Aligarh Muslim University, Aligarh 202002, India
2Centre of Excellence in Materials Science (Nanomaterials), Department of Applied Physics, Z.H. College of Engineering & Technology, Aligarh Muslim University, Aligarh 202002, India

Received 24 June 2013; Accepted 16 August 2013

Academic Editors: M. Alkondon, T. W. Stone, and M. Tohda

Copyright © 2013 Yasir Hasan Siddique et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Shehzad, F. Wahid, and Y. S. Lee, “Curcumin in cancer chemoprevention: molecular targets, pharmacokinetics, bioavailability, and clinical trials,” Archives of Pharmacology, vol. 343, no. 9, pp. 489–499, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. S. Purkayastha, A. Berliner, S. S. Fernando et al., “Curcumin blocks brain tumor formation,” Brain Research, vol. 1266, pp. 130–138, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. K.-Y. Yang, L.-C. Lin, T.-Y. Tseng, S.-C. Wang, and T.-H. Tsai, “Oral bioavailability of curcumin in rat and the herbal analysis from Curcuma longa by LC-MS/MS,” Journal of Chromatography B, vol. 853, no. 1-2, pp. 183–189, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Garcia-Alloza, L. A. Borrelli, A. Rozkalne, B. T. Hyman, and B. J. Bacskai, “Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model,” Journal of Neurochemistry, vol. 102, no. 4, pp. 1095–1104, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. Y. Sumanont, Y. Murakami, M. Tohda, O. Vajragupta, H. Watanabe, and K. Matsumoto, “Effects of manganese complexes of curcumin and diacetylcurcumin on kainic acid-induced neurotoxic responses in the rat hippocampus,” Biological and Pharmaceutical Bulletin, vol. 30, no. 9, pp. 1732–1739, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. W. J. Parak, D. Gerior, T. Pellegrino et al., “Biological applications of colloidal nanocrystals,” Nanotechnology, vol. 14, pp. R15–R27, 2003. View at Google Scholar
  7. H. Yang, “Nanoparticle-mediated brain-specific drug delivery, imaging, and diagnosis,” Pharmaceutical Research, vol. 27, no. 9, pp. 1759–1771, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. M. B. Feany and W. W. Bender, “A Drosophila model of Parkinson's disease,” Nature, vol. 404, no. 6776, pp. 394–398, 2000. View at Publisher · View at Google Scholar · View at Scopus
  9. J. B. Duffy, “GAL4 system in Drosophila: a fly geneticist's Swiss army knife,” Genesis, vol. 34, no. 1-2, pp. 1–15, 2002. View at Google Scholar · View at Scopus
  10. Y. H. Siddique, G. Ara, M. Faisal, and M. Afzal, “Protective role of Plumbago zeylanica extract against the toxic effects of ethinylestradiol in the third instar larvae of transgenic Drosophila melanogaster (hsp70-lacZ) Bg9 and cultured human peripheral blood lymphocytes,” Alternate Medicine Studies, vol. 1, pp. 26–29, 2011. View at Google Scholar
  11. R. G. Pendleton, F. Parvez, M. Sayed, and R. Hillman, “Effects of pharmacological agents upon a transgenic model of Parkinson's disease in Drosophila melanogaster,” Journal of Pharmacology and Experimental Therapeutics, vol. 300, no. 1, pp. 91–96, 2002. View at Publisher · View at Google Scholar · View at Scopus
  12. Y. H. Siddique, G. Ara, and M. Afzal, “Estimation of lipid peroxidation induced by hydrogen peroxide in cultured human lymphocytes,” Dose-Response, vol. 10, no. 1, pp. 1–10, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. K. J. Mitchell and B. E. Staveley, “Protocol for the detection and analysis of cell death in the adult Drosophila brain,” Drosophila Information Service, vol. 89, pp. 118–121, 2006. View at Google Scholar
  14. R. K. Das, N. Kasoju, and U. Bora, “Encapsulation of curcumin in alginate-chitosan-pluronic composite nanoparticles for delivery to cancer cells,” Nanomedicine, vol. 6, no. 1, pp. 153–160, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Iwai, “Properties of NACP/α-synuclein and its role in Alzheimer's disease,” Biochimica et Biophysica Acta, vol. 1502, no. 1, pp. 95–109, 2000. View at Publisher · View at Google Scholar · View at Scopus
  16. V. N. Uversky, J. Li, P. Souillac et al., “Biophysical properties of the synucleins and their propensities to fibrillate: inhibition of α-synuclein assembly by β- and γ-synucleins,” Journal of Biological Chemistry, vol. 277, no. 14, pp. 11970–11978, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. O. M. A. El-Agnaf, S. A. Salem, K. E. Paleologou et al., “Detection of oligomeric forms of α-synuclein protein in human plasma as a potential biomarker for Parkinson's disease,” FASEB Journal, vol. 20, no. 3, pp. 419–425, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Lorenz, J. Urban, U. Engelhardt, G. Baumann, K. Stangl, and V. Stangl, “Green and black tea are equally potent stimuli of NO production and vasodilation: new insights into tea ingredients involved,” Basic Research in Cardiology, vol. 104, no. 1, pp. 100–110, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. G. M. Cole, T. Morihara, G. P. Lim, F. Yang, A. Begum, and S. A. Frautschy, “NSAID and antioxidant prevention of Alzheimer's disease: lessons from in vitro and animal models,” Annals of the New York Academy of Sciences, vol. 1035, pp. 68–84, 2004. View at Publisher · View at Google Scholar · View at Scopus
  20. S. A. Frautschy, W. Hu, P. Kim et al., “Phenolic anti-inflammatory antioxidant reversal of Aβ-induced cognitive deficits and neuropathology,” Neurobiology of Aging, vol. 22, no. 6, pp. 993–1005, 2001. View at Publisher · View at Google Scholar · View at Scopus
  21. M. S. Wang, S. Boddapati, S. Emadi, and M. R. Sierks, “Curcumin reduces α-synuclein induced cytotoxicity in Parkinson's disease cell model,” BMC Neuroscience, vol. 11, article 57, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. T. M. Allen and P. R. Cullis, “Drug delivery systems: entering the main stream,” Science, vol. 303, no. 5665, pp. 1818–1822, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. W. M. Pardridge, “The blood-brain barrier: bottleneck in brain drug development,” NeuroRx, vol. 2, no. 1, pp. 3–14, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. V. A. Levin, “Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability,” Journal of Medicinal Chemistry, vol. 23, no. 6, pp. 682–684, 1980. View at Google Scholar · View at Scopus
  25. A. M. Celotto and M. J. Palladino, “Drosophila: a “model” model system to study neurodegeneration,” Molecular Interventions, vol. 5, no. 5, pp. 292–303, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. W. Jiang, B. Y. S. Kim, J. T. Rutka, and W. C. W. Chan, “Nanoparticle-mediated cellular response is size-dependent,” Nature Nanotechnology, vol. 3, no. 3, pp. 145–150, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. R. H. Müller and K. Peters, “Nanosuspensions for the formulation of poorly soluble drugs. I. Preparation by a size-reduction technique,” International Journal of Pharmaceutics, vol. 160, no. 2, pp. 229–237, 1998. View at Publisher · View at Google Scholar · View at Scopus
  28. F. Kesisoglou, S. Panmai, and Y. Wu, “Nanosizing—oral formulation development and biopharmaceutical evaluation,” Advanced Drug Delivery Reviews, vol. 59, no. 7, pp. 631–644, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. S. E. McNeil, “Nanotechnology for the biologist,” Journal of Leukocyte Biology, vol. 78, no. 3, pp. 585–594, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. A. J. Lees, J. Hardy, and T. Revesz, “Parkinson's disease,” The Lancet, vol. 373, no. 9680, pp. 2055–2066, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. J. B. Schulz, “Mechanisms of neurodegeneration in idiopathic Parkinson's disease,” Parkinsonism and Related Disorders, vol. 13, no. 3, pp. S306–S308, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. M. Farrer, J. Kachergus, L. Forno et al., “Comparsion of kindreds with Parkinsonisms and alpha synuclein genomic multiplication,” Annals of Neurology, vol. 55, no. 2, pp. 174–179, 2004. View at Publisher · View at Google Scholar · View at Scopus
  33. K. A. Conway, J.-C. Rochet, R. M. Bieganski, and J. Lansbury P.T., “Kinetic stabilization of the α-synuclein protofibril by a dopamine-α-synuclein adduct,” Science, vol. 294, no. 5545, pp. 1346–1349, 2001. View at Publisher · View at Google Scholar · View at Scopus
  34. B. I. Giasson, J. E. Duda, I. V. J. Murray et al., “Oxidative damage linked to neurodegeneration by selective α-synuclein nitration in synucleinopathy lesions,” Science, vol. 290, no. 5493, pp. 985–989, 2000. View at Publisher · View at Google Scholar · View at Scopus
  35. H. Fujiwara, M. Hasegawa, N. Dohmae et al., “α-synuclein is phosphorylated in synucleinopathy lesions,” Nature Cell Biology, vol. 4, no. 2, pp. 160–164, 2002. View at Publisher · View at Google Scholar · View at Scopus
  36. J. E. Galvin, B. Giasson, H. I. Hurtig, V. M.-Y. Lee, and J. Q. Trojanowski, “Neurodegeneration with brain iron accumulation, type 1 is characterized by α-, β-, and γ-synuclein neuropathology,” American Journal of Pathology, vol. 157, no. 2, pp. 361–368, 2000. View at Google Scholar · View at Scopus
  37. R. Sharon, I. Bar-Joseph, M. P. Frosch, D. M. Walsh, J. A. Hamilton, and D. J. Selkoe, “The formation of highly soluble oligomers of α-synuclein is regulated by fatty acids and enhanced in Parkinson's disease,” Neuron, vol. 37, no. 4, pp. 583–595, 2003. View at Publisher · View at Google Scholar · View at Scopus
  38. M. Caruana, T. Högen, J. Levin, A. Hillmer, A. Giese, and N. Vassallo, “Inhibition and disaggregation of α-synuclein oligomers by natural polyphenolic compounds,” FEBS Letters, vol. 585, no. 8, pp. 1113–1120, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. M. Naoi and W. Maruyama, “Future of neuroprotection in Parkinson's disease,” Parkinsonism and Related Disorders, vol. 8, no. 2, pp. 139–145, 2001. View at Publisher · View at Google Scholar · View at Scopus
  40. J.-M. Lü, J. Nurko, S. M. Weakley et al., “Molecular mechanisms and clinical applications of nordihydroguaiaretic acid (NDGA) and its derivatives: an update,” Medical Science Monitor, vol. 16, no. 5, pp. RA93–RA100, 2010. View at Google Scholar · View at Scopus
  41. K. Ono and M. Yamada, “Antioxidant compounds have potent anti-fibrillogenic and fibril-destabilizing effects for α-synuclein fibrils in vitro,” Journal of Neurochemistry, vol. 97, no. 1, pp. 105–115, 2006. View at Publisher · View at Google Scholar · View at Scopus
  42. R. Pal, M. Miranda, and M. Narayan, “Nitrosative stress-induced Parkinsonian Lewy-like aggregates prevented through polyphenolic phytochemical analog intervention,” Biochemical and Biophysical Research Communications, vol. 404, no. 1, pp. 324–329, 2011. View at Publisher · View at Google Scholar · View at Scopus
  43. J. Bieschke, J. Russ, R. P. Friedrich et al., “EGCG remodels mature α-synuclein and amyloid-β fibrils and reduces cellular toxicity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 17, pp. 7710–7715, 2010. View at Publisher · View at Google Scholar · View at Scopus
  44. K. A. Youdim, M. Z. Qaiser, D. J. Begley, C. A. Rice-Evans, and N. J. Abbott, “Flavonoid permeability across an in situ model of the blood-brain barrier,” Free Radical Biology and Medicine, vol. 36, no. 5, pp. 592–604, 2004. View at Publisher · View at Google Scholar · View at Scopus
  45. Y. Zhang, V. L. Dawson, and T. M. Dawson, “Oxidative stress and genetics in the pathogenesis of parkinson's disease,” Neurobiology of Disease, vol. 7, no. 4, pp. 240–250, 2000. View at Publisher · View at Google Scholar · View at Scopus
  46. D. A. Butterfield and J. Kanski, “Brain protein oxidation in age-related neurodegenerative disorders that are associated with aggregated proteins,” Mechanisms of Ageing and Development, vol. 122, no. 9, pp. 945–962, 2001. View at Publisher · View at Google Scholar · View at Scopus
  47. B. I. Giasson, J. E. Duda, S. M. Quinn, B. Zhang, J. Q. Trojanowski, and V. M.-Y. Lee, “Neuronal α-synucleinopathy with severe movement disorder in mice expressing A53T human α-synuclein,” Neuron, vol. 34, no. 4, pp. 521–533, 2002. View at Publisher · View at Google Scholar · View at Scopus
  48. R. A. Abbott, M. Cox, H. Markus, and A. Tomkins, “Diet, body size and micronutrient status in Parkinson's disease,” European Journal of Clinical Nutrition, vol. 46, no. 12, pp. 879–884, 1992. View at Google Scholar · View at Scopus
  49. K. N. Prasad, W. C. Cole, and B. Kumar, “Multiple antioxidants in the prevention and treatment of Parkinson's disease,” Journal of the American College of Nutrition, vol. 18, no. 5, pp. 413–423, 1999. View at Google Scholar · View at Scopus
  50. J. Long, H. Gao, L. Sun, J. Liu, and X. Zhao-Wilson, “Grape extract protects mitochondria from oxidative damage and improves locomotor dysfunction and extends lifespan in a Drosophila parkinson's disease model,” Rejuvenation Research, vol. 12, no. 5, pp. 321–331, 2009. View at Publisher · View at Google Scholar · View at Scopus
  51. Y. H. Siddique, G. Ara, S. Jyoti, and M. Afzal, “The dietary supplementation of nordihydroguaiaretic acid (NDGA) delayed the loss of climbing ability in Drosophila model of Parkinson's disease,” Journal of Dietary Supplements, vol. 9, no. 1, pp. 1–8, 2012. View at Publisher · View at Google Scholar · View at Scopus
  52. Y. H. Siddique, G. Ara, S. Jyoti, and M. Afzal, “Protective effect of curcumin in transgenic Drosophila melanogaster model of Parkinson's disease,” Alternate Medicine Studies, vol. 2, no. e3, pp. 7–9, 2012. View at Google Scholar
  53. Y. H. Siddique, G. Ara, S. Jyoti, and M. Afzal, “Effect of capsaicin on the climbing ability in Drosophila model of Parkinson's disease,” American Journal of Drug Discovery and Development, vol. 2, no. 1, pp. 50–54, 2012. View at Publisher · View at Google Scholar · View at Scopus
  54. S. Khan, S. Jyoti, F. Naz et al., “Effect of L-ascorbic acid on the climbing ability and protein levels in the brain of Drosophila model of Parkinson's disease,” International Journal of Neurosciences, vol. 122, no. 12, pp. 704–709, 2012. View at Google Scholar
  55. J. M. Abrams, K. White, L. I. Fessler, and H. Steller, “Programmed cell death during Drosophila embryogenesis,” Development, vol. 117, no. 1, pp. 29–43, 1993. View at Google Scholar · View at Scopus
  56. M. F. W. Festing, V. Baumans, R. D. Combes et al., “Reducing the use of laboratory animals in biomedical research: problems and possible solutions,” Alternatives to Laboratory Animals, vol. 26, no. 3, pp. 283–301, 1998. View at Google Scholar · View at Scopus
  57. D. J. Benford, A. B. Hanley, K. Bottrill et al., “Biomarkers as predictive tools in toxicity testing,” Alternatives to Laboratory Animals, vol. 28, no. 1, pp. 119–131, 2000. View at Google Scholar · View at Scopus
  58. R. B. Mythri and M. M. Srinivas Bharath, “Curcumin: a potential neuroprotective agent in Parkinson's disease,” Current Pharmaceutical Design, vol. 18, no. 1, pp. 91–99, 2012. View at Publisher · View at Google Scholar · View at Scopus